All In Biotech

Drug Trial Radar · NCT05394519

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

Feb 1, 2023

Primary completion

Jan 28, 2025

Study completion Feb 3, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Conditions

  • Overweight
  • Obesity
  • Type 2 Diabetes Mellitus

Interventions

  • CagrilintideDrug

    Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

  • SemaglutideDrug

    Semaglutide administered subcutaneously (s.c., under the skin) once-weekly

  • Placebo cagrilintideDrug

    Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly

  • Placebo semaglutideDrug

    Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)
  2. Achievement of greater than or equal to (≥) 5% weight reductionTime frame: From baseline (week 0) to end of treatment (week 68)

Locations

179 sites in 13 countries. Site status is shown where the registry gives one.

  • John Muir Physicians Network

    Concord, California

  • Headlands Research California, LLC

    Escondido, California

  • Providence Medical Foundation

    Fullerton, California

  • St. Jos Heritage Hlthcr_Fllrtn

    Fullerton, California

  • Diabetes/Lipid Mgmt & Res Ctr

    Huntington Beach, California

  • Clinical Trials Research

    Lincoln, California

  • Velocity Clin Res Los Angeles

    Los Angeles, California

  • Velocity Clin Res Wstlke

    Los Angeles, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • New West Physicians,Inc.

    Golden, Colorado

  • Clinical Res Of W Florida Inc

    Clearwater, Florida

  • Northeast Research Institute

    Fleming Island, Florida

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • Renstar Medical Research

    Ocala, Florida

  • AdventHealth Diab Inst

    Orlando, Florida

  • Florida Institute for Clinical Research, LLC

    Orlando, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • Endo Res Solutions Inc

    Roswell, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • Cotton-Oneill Diabetes and End

    Topeka, Kansas

  • L-MARC Research Center

    Louisville, Kentucky

  • Pennington Biom Res Ctr

    Baton Rouge, Louisiana

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan

  • International Diabetes Center

    Minneapolis, Minnesota

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Mercury Str Med Grp, PLLC

    Butte, Montana

  • AMC Community Endocrinology

    Albany, New York

  • Southgate Medical Group, LLP

    West Seneca, New York

  • Great Lakes Medical Research

    Westfield, New York

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina

  • Hillcrest Clinical Research

    Simpsonville, South Carolina

  • Holston Medical Group

    Kingsport, Tennessee

  • Amarillo Med Spec LLP

    Amarillo, Texas

  • Texas Diab & Endo, P.A.

    Austin, Texas

  • Texas Diab & Endo, P.A.

    Austin, Texas

  • Velocity Clinical Res-Dallas

    Dallas, Texas

  • North Texas Endocrine Center

    Dallas, Texas

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.